CD274 and esophageal cancer: More recently, KEYNOTE‐59034 found that pembrolizumab plus chemotherapy improved OS when compared with placebo plus chemotherapy as first‐line therapy for esophageal cancer with PD‐L1 CPS of 10 or more (median 13·9 vs.